Co-Authors
This is a "connection" page, showing publications co-authored by Fabiana Zingone and Edoardo Savarino.
Connection Strength
9.906
-
Starting a Biologic Therapy in IBD Patients Amid COVID-19: Hold, Careful Monitoring, or Testing? J Crohns Colitis. 2020 12 02; 14(12):1785.
Score: 0.916
-
Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. Dig Liver Dis. 2020 11; 52(11):1252-1253.
Score: 0.907
-
Risk of COVID-19 in celiac disease patients. Autoimmun Rev. 2020 10; 19(10):102639.
Score: 0.897
-
Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nocere. Dig Liver Dis. 2020 11; 52(11):1248-1249.
Score: 0.894
-
Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. J Allergy Clin Immunol Pract. 2020 09; 8(8):2790-2792.e1.
Score: 0.890
-
Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. J Clin Med. 2020 Jun 26; 9(6).
Score: 0.889
-
No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy. Dig Liver Dis. 2020 10; 52(10):1094-1096.
Score: 0.882
-
Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Dig Liver Dis. 2020 06; 52(6):604-605.
Score: 0.876
-
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020 06; 5(6):525.
Score: 0.874
-
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. J Clin Med. 2021 Jul 24; 10(15).
Score: 0.240
-
Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study. J Med Internet Res. 2020 11 02; 22(11):e19574.
Score: 0.228
-
Medical and gastroenterological education during the COVID-19 outbreak. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):447-449.
Score: 0.224
-
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? Gastroenterology. 2021 04; 160(5):1903-1904.
Score: 0.223
-
Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations. Dig Liver Dis. 2020 10; 52(10):1097-1098.
Score: 0.223
-
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. Inflamm Bowel Dis. 2020 04 11; 26(5):756-763.
Score: 0.219
-
Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. Gastroenterol Res Pract. 2019; 2019:5354320.
Score: 0.210
-
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. Expert Opin Biol Ther. 2019 02; 19(2):79-88.
Score: 0.201
-
Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. BMJ Open Gastroenterol. 2021 02; 8(1).
Score: 0.058
-
COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. Dig Liver Dis. 2020 10; 52(10):1071-1075.
Score: 0.055